Get startedLog in
    Picture of Cantargia AB logo

    CANTA — Cantargia AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapNeutral
    All News

    Brief: Cantargia Presents Phase 2 Clinical Data In Pancreatic Cancer With Nadunolimab

    Picture of Cantargia AB logoCantargia AB
    20/06/2024 06:05
    June 20 (Reuters) - Cantargia AB  CANTA.ST :
    * CANTARGIA PRESENTS PHASE 2 CLINICAL DATA IN PANCREATIC
CANCER
WITH NADUNOLIMAB AT ESMO GASTROINTESTINAL CANCER CONGRESS 2024
    * CANTARGIA AB - EFFICACY IN 73 PATIENTS TREATED WAS BETTER
THAN
EXPECTED FOR CHEMOTHERAPY ONLY BASED ON HISTORICAL DATA

Source text for Eikon:  ID:nMFN7qTmRr 
Further company coverage:  CANTA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))

    Recent news on Cantargia AB

    See all news